RUBY News and Press, Rubius Therapeutics Inc. From 05/11/22

Rubius Therapeutics (NASDAQ:RUBY) is trading lower into afternoon trading on Wednesday after H.C. Wainwright lowered the price target for clinical-stage biotech citing an update on the company’s Phase 1 trial for the cell therapy candidate, RTX-240 in advanced solid tumors. Announcing ...

Rubius Therapeutics press release (NASDAQ:RUBY): Q1 GAAP EPS of -$0.58 beats by $0.01. Cash, cash equivalents and investments of $176.5M, will provide a cash runway into the second half of 2023. For further details see: Rubius Therapeutics GAAP EPS of -$0.58 beats by $0.01

Presented Updated Clinical Data from Monotherapy Phase 1 Arm of RTX-240 Clinical Trial in Advanced Solid Tumors, Showing Clinical Responses with Favorable Tolerability in PD-(L)1 Refractory Disease Expanded Ongoing Phase 1 Arm of RTX-240 + Pembrolizumab to Focus on Non-Small Cell Lung C...

CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treat...

3 Penny Stocks For Your May 2022 Watchlist Finding the best penny stocks to buy in 2022 can be a daunting task for even the most experienced investors. With so many penny stocks to choose from and new companies emerging every day, it can be difficult to know where to start. To have ...

Shares of Rubius Therapeutics (NASDAQ:RUBY) are up 34% on Monday following the SEC filing of a purchase by a member of the company's board of directors. The filing shows that on April 21, David Epstein bought 30K shares at an average price of $1.44, for a total purchase price of $43...

Gainers: Nkarta (NKTX) +84%. ERYTECH Pharma (ERYP) +54%. Sunshine Biopharma (SBFM) +25%. Rubius Therapeutics (RUBY) +17%. Quoin Pharmaceuticals (QNRX) +12%. Losers: Eliem Therapeutics (ELYM) -55%. Clarus Therapeutics Holdings (CRXT) -54%....

After disappointing RTX-240 monotherapy data in advanced solid tumors patients, with only 3 responses of 27 patients, and no responses were observed with RTX-240 in AML patients, Morgan Stanley analyst Jeffrey Hung lowered the firm's price target on Rubius Therapeutics (RUBY -21.5%) to $4 fro...

Clinical-stage biotech, Rubius Therapeutics (NASDAQ:RUBY) is trading lower for the second straight session as investors react to Phase 1/2 data for its experimental cancer therapy RTX-240 that failed to meet Street expectations last week. Noting the lower than anticipated efficacy data, ...

Gainers: Veru (VERU) +196%. Hoth Therapeutics (HOTH) +126%. Altamira Therapeutics (CYTO) +54%. Iveda Solutions (IVDA) +37%. VNET Group (VNET) +30%. SailPoint Technologies Holdings (SAIL) +29%. Castor Maritime (CTRM) +25%. Datto Holding (MSP) +21%. Axcella Health (AXLA) +16%. TScan Therapeutic...